Neovia News
Neovia Oncology Files New Patent Following Discovery of Dual Topoisomerase I/II Catalytic Inhibition
Independent studies establish a differentiated mechanism for clinical-stage NEV-801 and reveal broader potential for Neovia’s proprietary oncology and ADC payload portfolio
Neovia Oncology Announces Completion of Phase I(a) Study of NEV-801, a Novel Dual Topoisomerase Drug-Drug Conjugate
Clinical Results Support Continued Development of First-in-Class Investigational Therapy Designed to Address Treatment Resistance in Solid Tumors
Neovia Oncology and CreativBio
Strategic partnership to study multiple drug resistant (MDR) in solid tumors.